RXi Pharmaceuticals Corporation RXII presented Phase 2 efficacy results for NeuVax™ in combination with trastuzumab (Herceptin®; Genentech/Roche) at the American Society of Clinical Oncology annual meeting.
The poster entitled, “Sequential administration of trastuzumab and a CD8 T cell-eliciting HER-2/neu peptide vaccine in breast cancer patients compared to trastuzumab alone,” was presented during the “Breast Cancer HER2/ER” poster session on Monday, June 6, 2011. RXi is developing NeuVax, a CD8 T-cell eliciting immunotherapy, for the adjuvant treatment of low to intermediate HER2 expressing breast cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in